Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY: HAE )

73.49 -0.04 (-0.05%)
Official Closing Price Updated: 4:10 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 535,580
Open 74.20
Bid (Size) 66.00 (1)
Ask (Size) 74.73 (1)
Prev. Close 73.53
Today's Range 71.76 - 74.39
52wk Range 69.29 - 97.97
Shares Outstanding 51,029,618
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering. 
Via Chartmill
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga

Performance

YTD
-6.26%
-6.26%
1 Month
-10.45%
-10.45%
3 Month
-3.23%
-3.23%
6 Month
-15.13%
-15.13%
1 Year
-11.03%
-11.03%

More News

Read More
The Latest Analyst Ratings For Haemonetics
Via Benzinga
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
Via Chartmill
Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
NYSE:HAE is not too expensive for the growth it is showing.
Via Chartmill
Despite its growth, NYSE:HAE remains within the realm of affordability.
Via Chartmill
What Analysts Are Saying About Haemonetics Stock
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Via Chartmill
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
NYSE:HAE stands out as a growth opportunity that won't break the bank.
Via Chartmill
Analyst Expectations For Haemonetics's Future
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Via Chartmill
NYSE:HAE stands out as a growth opportunity that won't break the bank.
Via Chartmill
Looking for growth without the hefty price tag? Consider NYSE:HAE.
Via Chartmill
NYSE:HAE, a growth stock which is not overvalued.
Via Chartmill
Sotera Health Appoints Christopher Simon to the Board of Directors
From Sotera Health Services, LLC
Via GlobeNewswire
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Via Benzinga
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
These 3 Companies Boast Bright Outlooks
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
4 Analysts Assess Haemonetics: What You Need To Know
Via Benzinga
HAE Stock Earnings: Haemonetics Beats EPS, Beats Revenue for Q4 2024
Via InvestorPlace
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.